A new preclinical study from Complutense University has found that CB1 receptor myelin repair mechanisms depend on intact endocannabinoid signaling at a critical cellular window. Researchers removed CB1 receptors specifically from newly formed oligodendrocytes in mice and observed that remyelination failed, neuroinflammation worsened, and motor recovery did not occur. While the findings are in animals and no cannabinoid was tested, they establish a specific mechanistic role for the endocannabinoid system in the brain’s ability to repair itself after injury.
Long-Term Cannabis Therapy May Change MS Spasticity Outcomes
Cannabis for MS spasticity was associated with meaningful symptom improvement in a new meta-analysis involving 2,544 multiple sclerosis patients across nine trials. The strongest benefits emerged with longer treatment duration, while short-term effects were more modest. The findings may reshape how clinicians counsel patients about expectations, timing, and long-term cannabinoid therapy for neurological symptoms.
Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.
A new consensus from Italian neurologists proposes enhancing the endocannabinoid system multiple sclerosis treatment approach for patients with relapse-free disease. The algorithm combines cannabinoid agents with lifestyle interventions to address residual symptoms like spasticity in MS patients on high-efficacy therapies.
Daily Temporal Associations Between Use of Psychoactive Substances and Fatigue, Pain, Stress, and Depressive Symptoms in People With Multiple Sclerosis.
A real-time smartphone-based study of 258 MS patients revealed that higher pain levels drive increased cannabis use and decreased alcohol consumption. This research using ecological momentary assessment provides clinical evidence that MS patients make deliberate, symptom-driven substance use decisions throughout their daily lives.
A sesquiterpene-rich essential oil from Cannabis sativa L. attenuates symptoms and neuroinflammation in experimental autoimmune encephalomyelitis model through a CB2-mediated signalling.
Researchers found that cannabis essential oil neuroinflammation reduction occurred through CB2 receptor activation in an experimental multiple sclerosis model. The sesquiterpene-rich formulation improved pain, motor function, and emotional symptoms without psychoactive effects. While promising, this preclinical evidence requires human validation before clinical application.
Discrepancies between subjective and objective cognition in persons with multiple sclerosis: Exploring the role of cannabis use.
Research examining cannabis cognitive effects in multiple sclerosis patients found that cannabis users report greater perceived cognitive deficits than non-users. This cross-sectional study of 847 MS patients provides important insights into the perception-reality gap regarding cannabis and cognition in neurological disease management.
Daily Temporal Associations Between Use of Psychoactive Substances and Fatigue, Pain, Stress, and Depressive Symptoms in People With Multiple Sclerosis.
To examine daily within-person associations between symptoms reported by people with multiple sclerosis (MS) and psychoactive substance use using ecological …
Ozone smog may increase the risk of MS in children: Study – Multiple Sclerosis News Today
✦ New CED Clinical Relevance #80High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic Multiple SclerosisPediatric NeurologyEnvironmental HealthAutoimmune DiseaseAir Pollution Why This MattersThis environmental epidemiology finding adds...
Wim Hof method, lifestyle changes reduce inflammation in new MS study
✦ New CED Clinical Relevance #80High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic Multiple SclerosisInflammationMind-Body MedicineComplementary MedicineAutoimmune Why This MattersMultiple sclerosis patients frequently seek complementary approaches...
Scientists zero in on CD29 protein marker as key driver of MS in new study
✦ New CED Clinical Relevance #80High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic Multiple SclerosisInflammationBiomarkersNeurological ConditionsResearch Why This MattersCD29 protein identification as a key driver in...